Announcing Deep Origin as a sponsor of ARDD 2025

(Press-News.org) The University of Copenhagen is excited to announce Deep Origin as the latest tier 3 sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online.

Deep Origin is building hybrid mechanistic, physics and AI-based models that help researchers design, test, and filter therapeutics in silico – particularly for challenging disease areas such as aging. The company's vision is to construct an interconnected system of models that spans the scales of biology, from quantum mechanical interactions to gene network dynamics and cell state; such models can ultimately enable creation of virtual cells and deeper understanding of biological function. Deep Origin's hybrid AI-mechanistic approaches enable generalization beyond available data, helping drive novel biological insights. Deep Origin provides broad access to many of its atomistic drug discovery tools through an intuitive SaaS AI assistant and APIs, as well as through partnerships.

At ARDD 2025, Deep Origin will host two presentations: CEO Michael Antonov will share an overview of its approach to building virtual cells for drug discovery and longevity on the Main Stage at 13:20 on August 29. CSO Garegin Papoian will present a technical deep dive into the integration of molecular models at multiple scales to enable discovery of molecules that modulate protein-protein interactions in the Physics in Aging Track at 9:50 on August 26.

“We look forward to connecting with the AARD community at this year’s conference to share the latest in the productivity of drug discovery. This event is closely aligned with our vision to model, organize, and accelerate biological R&D, enabling cures through deep understanding of science.” said Michael Antonov, CEO of Deep Origin.

ARDD has grown to become the largest and most important conference in longevity biotechnology. Each year, ARDD brings together a unique mix of academic luminaries, biotech innovators, investors, top pharmaceutical executives, physicians, and related health care professionals to discuss the latest advancements in aging research and the event provides unique opportunities to connect with brilliant minds, fostering collaboration and showcasing groundbreaking research in the field.

“We are extremely honored to host Professors Meldal and Levitt at ARDD2025. Their Nobel prize winning discoveries have been instrumental for drug development and molecular design in part through modelling of proteins and molecules, and in part through the ability to easily create new molecules. It is therefore a great pleasure that they are joining our conference.” said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.

“We are really excited for ARDD2025, especially with Nobel Laureates Morten Meldal and Michael Levitt joining us. Their groundbreaking contributions have had a lasting impact on drug discovery, and having them at the conference is sure to make it an unforgettable experience.” said Daniela Bakula, Ph.D., University of Copenhagen.

“For 12 years, the Aging Research and Drug Discovery (ARDD) forum grew in size and in quality. It became the world’s main platform for academia-pharma-startup-investor partnership and dialogue. In 2025, the conference will feature the Nobel laureates, pharmaceutical industry executives and healthcare delivery leaders. ARDD is a unique platform for advancing longevity biotechnology around the world.” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine. 

“At ARDD we strive to highlight the cutting-edge research and clinical applications in a new discipline of healthy longevity medicine. Having Nobel laureates join and speak at the ARDD conference underscores the critical importance of grounding longevity science and medicine in evidence-based, scientifically rigorous approaches.” said Prof.Dr.Evelyne Bischof, the organizer of the Longevity Medicine Days.

Aging research has become a great platform for advancing drug discovery with blockbuster potential, with pharmaceutical leaders like Novartis, Biogen, and Eli Lilly actively supporting this transformative field. ARDD has established itself as the go-to venue where scientists and pharma companies collaborate, share insights, and launch aging-focused research initiatives. In 2024, industry leaders such as Eli Lilly, Novartis, Regeneron, Biogen, and Lundbeck presented their latest research at ARDD, highlighting the meeting's pivotal role in advancing healthspan and longevity science. Be part of ARDD 2025 and contribute to shaping the future of medicine.

For further information, images or interviews, please contact:

ardd@pharma.ai

 

About Aging Research for Drug Discovery Conference

At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we will have a special day called Longevity Medicine Day, specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. Our quest to extend the healthy lifespan of everyone on the planet.

 

END